Recent Press Releases

Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone)

Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone) Dublin, Ireland – January 23, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) notes...

Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity (22 January 2015)

Bagsværd, Denmark, 22 January 2015 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive...

Hospira Issues a Voluntary Nationwide Recall of One Lot of 0.9% Sodium Chloride Injection, USP, 250 mL Due to Particulate Matter

FOR IMMEDIATE RELEASE — January 20, 2015 — LAKE FOREST, Ill., — Hospira, Inc. (NYSE: HSP), announced today it will initiate a voluntary nationwide recall of one lot of 0.9% Sodium...

NICE recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack in final draft guidance

In final draft guidance published today NICE has confirmed its earlier positive draft decision recommending rivaroxaban (Xarelto, Bayer Healthcare), in combination with clopidogrel and aspirin, or...

Celgene Receives Positive CHMP Opinion for ABRAXANE(R) for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

Celgene Receives Positive CHMP Opinion for ABRAXANE ^(R) for First-Line Treatment of Patients with Non-Small Cell Lung Cancer In Europe, Lung Cancer is the 4 ^th most commonly diagnosed cancer and...

Morningstar Names John Martin of Gilead Sciences as its 2014 CEO of the Year

CHICAGO, Jan. 21, 2015—Morningstar, Inc. (NASDAQ: MORN), a leading provider of independent investment research, today named John Martin of Gilead Sciences the recipient of its 2014 CEO of the...

Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients

Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients Offering a new treatment option for patients, Cosentyx is the...

Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

NEW YORK, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced the pricing of an underwritten public offering of common stock consisting of 9,166,667 shares...

GPhA President and CEO Ralph G. Neas to Step Down in the Fall of 2015

WASHINGTON DC (January 20, 2015) — The Generic Pharmaceutical Association (GPhA) announced today that Ralph G. Neas, President and CEO, would be stepping down from his position in the fall of...

Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results:

2014 Fourth-Quarter Sales of $18.3 Billion Decreased 0.6%; EPS was $0.89

NEW BRUNSWICK, N.J., Jan.

Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman

Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman Bristol-Myers Squibb Media:Jennifer Fron Mauer, 609-252-6579 or...

Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIV

Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIV Card Enables Eligible Patients to Pay No More than $75 for their BELVIQ Prescription*...

Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results:

2014 Fourth-Quarter Sales of $18.3 Billion Decreased 0.6%; EPS was $0.89 2014 Full-Year Sales of $74.3 Billion Increased 4.2%; Full-Year EPS was $5.70 Excluding Special Items, 2014 Fourth-Quarter EPS...

European Label Update of Bayer's Xarelto(R) Now Including Guidance for Use in Patients with Atrial Fibrillation Undergoing Cardioversion

BERLIN, Jan. 20, 2015 /PRNewswire/ -- Bayer HealthCare today announced the inclusion of specific guidance for doctors treating patients with non-valvular atrial fibrillation (AF) undergoing...

Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative

Consortia funded through the IMI Ebola+ Programme Supported by the European Commission

NEW BRUNSWICK, N.J.,

Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion

SOURCE Depomed, Inc. Conference call today at 5:00 p.m. EST - Transformative acquisition enhances Depomed's position as a leading pain and neurology focused specialty pharmaceutical company -...

Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution

TITUSVILLE, N.J., Jan. 15, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (JPI) today announced it has entered into a definitive agreement with Depomed, Inc. to divest its U.S. license rights to...